Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA 10,650
+150 (1.43%)
Aug 10, 2026, 5:27 PM IDT
TLV:TEVA Ratios and Metrics
Market cap in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 123,524 | 114,152 | 91,081 | 42,146 | 35,617 | 27,480 | |
Market Cap Growth | 91.47% | 25.33% | 116.11% | 18.33% | 29.61% | -19.18% |
Enterprise Value | 163,224 | 161,627 | 150,359 | 109,242 | 106,456 | 99,359 |
Last Close Price | 106.50 | 100.90 | 81.01 | 38.15 | 32.99 | 26.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 58.73 | 25.40 | - | - | - | 21.19 |
PS Ratio | 2.39 | 2.08 | 1.51 | 0.74 | 0.68 | 0.56 |
PB Ratio | 5.35 | 4.52 | 4.37 | 1.44 | 1.18 | 0.79 |
P/FCF Ratio | 30.78 | 31.19 | 33.39 | 13.90 | 9.72 | 37.44 |
P/OCF Ratio | 21.85 | 21.71 | 20.05 | 8.56 | 6.37 | 11.07 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.14 | 2.94 | 2.50 | 1.91 | 2.03 | 2.01 |
EV/EBITDA Ratio | 12.34 | 10.23 | 9.31 | 6.99 | 7.63 | 7.25 |
EV/EBIT Ratio | 16.53 | 12.83 | 12.24 | 9.52 | 11.37 | 10.38 |
EV/FCF Ratio | 40.68 | 44.16 | 55.12 | 36.03 | 29.06 | 135.36 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.18 | 2.18 | 3.18 | 2.50 | 2.52 | 2.10 |
Debt / EBITDA Ratio | 3.84 | 3.39 | 3.98 | 4.53 | 5.26 | 5.19 |
Debt / FCF Ratio | 12.54 | 15.01 | 24.28 | 24.08 | 20.80 | 99.97 |
Net Debt / Equity Ratio | 1.71 | 1.73 | 2.60 | 2.10 | 2.19 | 1.91 |
Net Debt / EBITDA Ratio | 3.10 | 2.76 | 3.36 | 3.93 | 4.75 | 4.86 |
Net Debt / FCF Ratio | 9.83 | 11.91 | 19.87 | 20.25 | 18.11 | 90.80 |
Asset Turnover | 0.43 | 0.43 | 0.40 | 0.36 | 0.33 | 0.32 |
Inventory Turnover | 2.45 | 2.69 | 2.41 | 2.09 | 2.08 | 2.02 |
Quick Ratio | 0.46 | 0.54 | 0.50 | 0.54 | 0.57 | 0.61 |
Current Ratio | 0.88 | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 |
Return on Equity (ROE) | 9.69% | 20.79% | -28.30% | -7.36% | -25.19% | 4.09% |
Return on Assets (ROA) | 5.13% | 6.17% | 5.09% | 4.55% | 3.63% | 3.91% |
Return on Invested Capital (ROIC) | 15.21% | 18.73% | 14.74% | 12.10% | 8.85% | 6.18% |
Return on Capital Employed (ROCE) | 13.50% | 14.50% | 12.70% | 10.20% | 8.20% | 8.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.70% | 3.94% | -6.55% | -4.78% | -24.15% | 4.72% |
FCF Yield | 3.25% | 3.21% | 3.00% | 7.20% | 10.29% | 2.67% |
Buyback Yield / Dilution | -2.24% | -2.83% | -1.07% | -0.81% | -0.27% | -1.10% |
Total Shareholder Return | -2.24% | -2.83% | -1.07% | -0.81% | -0.27% | -1.10% |